Prostate Cancer: Quo Vadis?
Author:
Publisher
Elsevier BV
Subject
Urology
Reference11 articles.
1. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015
2. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017
3. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011
4. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer;Efstathiou;Eur Urol,2015
5. Radiotherapy to the primary tumor for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial;Parker;Lancet,2018
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Validity and Future of Primary Androgen Deprivation Therapy in Prostate Cancer. Integration in the Era of New Agents Targeting the Androgen Receptor;Archivos Españoles de Urología;2023
2. Role of smartphone devices in precision oncology;Journal of Cancer Research and Clinical Oncology;2022-10-17
3. In-bore MR prostate biopsy — initial experience;Endokrynologia Polska;2022-07-18
4. Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities;The Prostate;2021-06-25
5. Do prostate cancer-related mobile phone apps have a role in contemporary prostate cancer management? A systematic review by EAU young academic urologists (YAU) urotechnology group;World Journal of Urology;2020-04-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3